Metrics cut 3
- FY27 revenue growth guidance cut to 30-40% (from 40% earlier)
- Egypt FY27 revenue guidance cut to ₹30-35 crores (from ₹50-60 crores)
- Metallic soaps plant commencement delayed to Sept-Oct 2026 (from August)
Event Participants
Executives
2 Krishna Rana, Chairman and Managing Director; Ashok Bothra, Chief Financial Officer
Analysts
6 Arnav Sakhuja, Ambit Investment Advisors; Bhagwat Nayak, Analyst; Bhargav Buddhadev, Analyst; Rakesh Sharma, Analyst; Surbhi Mishra, JPMorgan Chase
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹108.9 crores | Down from ₹115.4 crores YoY, impacted by capacity transition/ramp-up at Palghar and lower volume of high-margin lead-free PVC. |
| Consolidated EBITDA | ₹13.44 crores (12.34% margin) | Down from ₹15.16 crores (13.14% margin) YoY; margin decline partly due to one-off ECL reversal and lower selling expenses. |
| Consolidated PBT | ₹14.95 crores | Down from ₹17.82 crores YoY due to product mix and ramp-up costs. |
| Consolidated PAT | ₹11.13 crores | Down from ₹13.07 crores YoY; EPS at ₹2.03. |
| Standalone Revenue | ₹110.4 crores | Up 7.3% from ₹102.9 crores YoY, supported by rest of operations. |
| Standalone EBITDA | ₹12.85 crores (11.64% margin) | Down from ₹13.72 crores (13.33% margin) YoY due to product mix change and higher depreciation. |
| Standalone PBT | ₹13.2 crores | Down from ₹16.88 crores YoY; PAT at ₹9.58 crores, EPS ₹1.74. |
| Capacity (India) | ~85,000 TPA post ramp-up | Includes 60,000 TPA expansion at Palghar (24,000 TPA lead-free PVC, 24,000 TPA CPVC, 12,000 TPA lubricants) and 6,000 TPA storage (commencing Sept-Oct 2026). |
| Capacity (Egypt) | 60,000 TPA | Total investment ~₹68 crores; commercial production expected before 31 December 2026. |
| IPO Proceeds Utilized | ₹165.9 crores (of ₹211.8 crores) | ₹15 crores utilized in Q1 FY27; balance ₹45.9 crores as of 30 June 2026. |
| Capex | Palghar ~₹71 crores, Egypt ~₹67 crores | Palghar commissioned 21 May 2026; Egypt on track for December 2026. |
Geographic & Segment Commentary
India (Domestic): Revenue growth was driven by stabilizers and additives with the Palghar expansion now operational. Q1 FY27 was a transition quarter with utilization currently at 30-35% for the new facility, expected to ramp up meaningfully through Q2-Q3 FY27. Demand for pipes was muted in the quarter but has picked up from August, supported by stabilized and rising PVC prices.
International (Exports & Egypt): The Egypt facility remains a key strategic focus, with commercial production targeted before 31 December 2026. It offers duty-free access to the US (via QIZ) and South American markets, expected to become a meaningful growth and margin driver in FY28. Initial revenue estimate for Egypt in FY27 has been scaled down from ₹50-60 crores to ₹30-35 crores, being a partial ramp-up contribution in Q4.
CPVC & Lead-Free Additives: CPVC additives are in an early growth phase with competition limited to a few players (e.g., one domestic player). Margins are currently at ~18%, improving from initial 3-7% contribution levels, and management targets 20-21% margins by Q4 FY27 as supply chains stabilize and demand supports pricing.
Oleochemicals (Platinum Oleochemicals Pvt Ltd): Commenced sales in Q1 FY27 with revenue of ~₹5.3-5.5 crores, including exports to Malaysia and Turkey. FY27 target is ₹65-70 crores; three-year revenue aspiration of ₹150-200 crores. Currently following a CDMO route for seed marketing, with plans to set up manufacturing in ~1.5 years.
Company-Specific & Strategic Commentary
Capacity Expansion & Commissioning: Palghar facility fully operational 21 May 2026 (60,000 TPA); total India capacity scaling to 85,000+ TPA including 6,000 TPA storage commencing Sept-Oct 2026, reflecting a shift from capacity creation to operational utilization.
Egypt Manufacturing Hub: Strategic plant with total investment ₹68 crores, 60,000 TPA capacity; 100% lead stabilizer product mix targeting Western markets where lead-based products have higher demand. Enables cost-competitive exports to US and South America via favorable trade agreements.
Product Mix Enhancement: Continued shift toward higher-value lead-free and specialty stabilizers, CPVC additives, and new oleochemical derivatives. Management emphasized that contribution margins in lead-free/calcium-zinc business remain intact, with lower blended margins due to CPVC's learning curve.
Competitive Positioning: Management sees limited competition in CPVC additives; lead-free PVC segment has only 3 notable competitors (Baerlocher, Reagens, Goldstab). Lubrizol's CPVC resin investment in India is viewed as complementary rather than a threat, as it accelerates adoption of separate resin-additive models, benefiting Platinum.
Diversification Initiatives: Platinum Oleochemicals commenced sales with exports; River Life Sciences pharma business remains in early stage with business model identification and potential collaborations, no meaningful revenue yet.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth (FY27) | 30-40% | Management affirmed maintaining the previous guidance of 30-40% growth (updated from earlier "40%"); pace depends on demand pickup from August-December and ramp-up of Palghar. |
| EBITDA Margin (Going Forward) | 13-15% | CFO reiterated this target, assuming normalized shipping costs, improved CPVC margins, and higher capacity utilization. |
| PAT Margin (Near-Term) | 11-12% | CMD guided PAT margin of 11-12% in the coming months; assumes recovery of contribution margin in CPVC and sustained cost discipline. |
| Egypt Revenue (FY27) | ₹30-35 crores (from December) | Reduced from initial ₹50-60 crores; commercial production expected by 31 December 2026. |
| Palghar Revenue Potential (3-Year Horizon) | ₹700-800 crores | Guided peak potential over next three years from new Palghar facility, assuming full ramp-up. |
| Egypt Revenue Potential (3-Year Horizon) | ₹250-300 crores | Guided peak potential over three years; product mix primarily lead stabilizers, with lower ASPs vs. India. |
| Overall CAGR (Top-line, 3 Years) | ~35% | Management reiterated a 35% top-line CAGR expectation over a three-year period. |
| Oleochemicals Revenue (FY27) | ₹65-70 crores; ₹150-200 crores (3-year) | Based on seed marketing via CDMO; manufacturing facility planned in ~1.5 years. |
| Metallic Soaps Plant | Commencement Sept-Oct 2026 | Initially expected August, delayed due to equipment; startup factored into FY27 guidance. |
Risks & Constraints
| Risk | Context |
|---|---|
| Demand Softness in PVC Pipes | Pipe demand was in degrowth in Q1 FY27 due to PVC price volatility and farmer/retailer deferral. Demand has picked up from August with stabilized PVC prices; management confident of strong Aug-Dec period. |
| Geopolitical / Shipping Disruptions | War scenario driving high freight, CFS charges, and delayed shipments impacting contribution margins, as costs can't be fully passed on in real-time to customers. This is a temporary but material margin drag. |
| CPVC Margin Recovery Delay | CPVC margins currently at ~18% vs. 20-22% potential; recovery expected only in Q3-Q4 FY27 as demand-supply gap narrows. |
| Raw Material Supply Constraints | Imported raw material availability impacted by shipping disruptions, forcing local purchases at higher costs, pressuring margins in the interim. |
| Execution Risk – Egypt (Timeline) | Commercial production before December 2026 is critical; any delay would impact FY27 revenue (₹30-35 crores factored) and FY28 growth visibility. Management sees no major bottlenecks. |
| Product Mix Shift Impacting Margins | Lower contribution of high-margin lead-free PVC in Q1 led to margin decline. Sustainability of 13-15% EBITDA margin depends on scale-up of new capacity and mix normalization. |
Q&A Highlights
Demand & Industry Outlook
Question: How was pipes demand in July and August? (Arnav Sakhuja)
Answer: Pipe demand was in degrowth in the last quarter as seen in pipe companies' results. Demand has picked up from August as PVC prices have stabilized and begun rising, prompting farmers and retailers to purchase. Expects good demand from August to December. (Krishna Rana)
Question: Is the 40% revenue growth guidance still maintained? (Bhargav Buddhadev)
Answer: Will maintain 30-40% growth. Already on track despite demand headwinds from the war. (Krishna Rana)
Margins & Product Mix
Question: What are CPVC margins and when will they reach 20-22%? (Arnav Sakhuja)
Answer: Currently at 18%, will reach 20-21% by Q4 FY27. Demand-supply gap and raw material shipment disruptions are temporarily impacting margins. (Krishna Rana)
Question: How much of the margin improvement is structural vs temporary? (Surbhi Mishra)
Answer: Q1 margin held up due to lower other expenses (no exhibitions) and ECL reversal on debtors. Without these, margins would have been lower. Utilization was 30-35% as the plant was fully operational from 21 May 2026. (Ashok Bothra)
Question: Were there one-offs in other income or forex? (Surbhi Mishra)
Answer: There was a forex gain of ~₹1.1 crore reflected in other income. (Ashok Bothra)
Capacity and Growth
Question: What is the project-wise capex, status, and revenue potential? (Rakesh Sharma)
Answer: Egypt capex ~₹67-68 crores, with expected revenue of ₹250-300 crores over three years. Palghar capex ~₹71 crores, expected revenue of ₹700-800 crores over three years. Overall top-line CAGR of ~35% over three years. (Ashok Bothra, Krishna Rana)
Question: What is the status of the metallic soaps plant? (Unidentified Analyst)
Answer: Now expected to commence in September-October instead of August due to equipment delay. This was factored into the FY27 guidance. (Ashok Bothra)
Competition & Strategy
Question: How does Lubrizol's CPVC investment with Grasim affect Platinum? (Krish Desai via chat)
Answer: It's complementary. Lubrizol will make CPVC resin (75% of compound), while Platinum supplies additives (25%). The shift from compound to separate resin + additives benefits Platinum. Reliance and others also building resin capacity will broaden the market. (Krishna Rana)
Question: What is the competitive intensity in lead-free and CPVC additives? (Bhagwat Nayak)
Answer: Only 3 major competitors in lead-free (Baerlocher, Reagens, Goldstab). Each supplier has pockets; pricing discipline is maintained across the industry. No major pricing pressure expected. (Krishna Rana)
New Businesses
Question: What are the plans for oleochemicals and pharma (River Life Sciences)? (Surbhi Mishra)
Answer: Oleochemicals has started seed marketing, targeting ₹65-70 crores in FY27 and ₹150-200 crores in 3 years; manufacturing to begin in ~1.5 years. River Life Sciences is still identifying its business model; in negotiations for collaborations with overseas companies. (Krishna Rana)
Question: What margins to expect in oleochemicals for FY27? (Khushboo Gandhi via chat)
Answer: Margins are lower currently due to CDMO route; will increase once manufacturing facility is set up. (Ashok Bothra)
Egypt and Working Capital
- Question: How much additional working capital is anticipated for Egypt? (Operator)
- Answer: Roughly a three-month working capital cycle is expected on account of Egypt operations. (Ashok Bothra)
Key Takeaway
Platinum Industries reported Q1 FY27 consolidated revenue of ₹108.9 crores, down 6% YoY, with PAT of ₹11.1 crores (11.13 crores) as the company navigated capacity transition and ramp-up. Standalone revenue grew 7.3% to ₹110.4 crores, but margins were compressed (EBITDA 11.64% standalone, 12.34% consolidated) due to lower contribution from high-margin lead-free PVC and shipping disruptions from the war. The Palghar facility (60,000 TPA) is now fully operational, taking total India capacity to 85,000+ TPA, with utilization currently at 30-35% and expected to ramp through Q2-Q3. Egypt remains on track for commercial production by December 2026, with initial FY27 revenue guidance reduced to ₹30-35 crores. Management reaffirmed 30-40% revenue growth guidance for FY27, 13-15% EBITDA margins going forward, and a ~35% top-line CAGR over three years. Key watch points include demand recovery in pipes (which has started), CPVC margin progression toward 20-21% by Q4, and capex/commissioning discipline across Palghar and Egypt.